ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system can be used alongside Myriad’s existing tissue-based diagnostic assays.
The project will see ANGLE’s R&D team process blood samples from cancer patients with Parsortix, which captures intact cancer cells for downstream analysis. Results will then be compared with matched patient tissue samples using Myriad Genetics’ established tissue assays.
By shifting from tissue biopsies to a simple blood test, researchers hope to improve patient access to genomic information, offering a less invasive and potentially faster alternative to conventional biopsy procedures.
Andrew Newland, CEO of ANGLE, said: “We are delighted to be working with Myriad Genetics, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system. This collaboration has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data.”
Additional details of the agreement remain confidential, but the companies intend for the collaboration to broaden the use of liquid biopsy in precision oncology.
ANGLE’s Parsortix technology has already been approved by the US Food and Drug Administration for use in harvesting CTC. Additionally, more than 110 peer-reviewed publications support its performance.